Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer

BACKGROUND: The majority of patients with newly diagnosed metastatic prostate cancer (PC) initially respond to androgen deprivation therapy (ADT) and are classified as metastatic castration-sensitive PC (mCSPC). Following months to years of ADT, the disease tends to become resistant to ADT. Recent r...

Descripción completa

Detalles Bibliográficos
Autores principales: Isaksson, Jenny, Green, Henrik, Papantoniou, Dimitrios, Pettersson, Linn, Anden, Mats, Rosell, Johan, Åvall-Lundqvist, Elisabeth, Elander, Nils Oskar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Retrospective Cohort Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641012/
https://www.ncbi.nlm.nih.gov/pubmed/34909396
http://dx.doi.org/10.5306/wjco.v12.i11.1009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641012/
https://www.ncbi.nlm.nih.gov/pubmed/34909396
http://dx.doi.org/10.5306/wjco.v12.i11.1009

Ejemplares similares